Burrows Scott L sold $658K of SYRE
Burrows Scott L (Chief Financial Officer) sold 7,500 shares of Spyre Therapeutics, Inc. (SYRE) at an average of $87.74 ($87.55–$88.37, $0.66M total) across 2 trades on 2026-07-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure provides transparency on CFO selling activity but does not include new guidance, trial results, deals, or regulatory actions.
Market read
Traders may monitor for follow-on insider activity, but this specific filing is unlikely to drive a major repricing absent other catalysts.
What to watch
Insider sales can be routine; without context on total insider holdings, option exercises, or prior sale cadence, the signal is weak.
Background
The article is a primary-source SEC Form 4 insider transaction for Spyre Therapeutics, Inc. (SYRE).
Ticker impact
Spyre Therapeutics CFO Burrows Scott L sold 7,500 shares in open-market transactions under a pre-arranged 10b5-1 plan on 2026-07-01.
Likely limited near-term impact; any reaction should be small and quickly absorbed given the 10b5-1 pre-arranged nature.
Form 4 shows a scheduled open-market sale (10b5-1) with no accompanying new company-specific operational or financial information.
Market effects
No sector read-through; this is a single-company insider transaction.
None indicated.
None indicated.
Counterpoint
Because the sale is under a 10b5-1 plan, it may reflect diversification or liquidity needs rather than bearish expectations.
Key entities
- issuerSpyre Therapeutics, Inc.
Subject of the Form 4 insider transaction; CFO sold shares under a 10b5-1 plan.
- insiderBurrows Scott L
Chief Financial Officer who executed open-market sales of SYRE shares.
